Your browser doesn't support javascript.
loading
YWHAE loss of function causes a rare neurodevelopmental disease with brain abnormalities in human and mouse.
Denommé-Pichon, Anne-Sophie; Collins, Stephan C; Bruel, Ange-Line; Mikhaleva, Anna; Wagner, Christel; Vancollie, Valerie E; Thomas, Quentin; Chevarin, Martin; Weber, Mathys; Prada, Carlos E; Overs, Alexis; Palomares-Bralo, María; Santos-Simarro, Fernando; Pacio-Míguez, Marta; Busa, Tiffany; Legius, Eric; Bacino, Carlos A; Rosenfeld, Jill A; Le Guyader, Gwenaël; Egloff, Matthieu; Le Guillou, Xavier; Mencarelli, Maria Antonietta; Renieri, Alessandra; Grosso, Salvatore; Levy, Jonathan; Dozières, Blandine; Desguerre, Isabelle; Vitobello, Antonio; Duffourd, Yannis; Lelliott, Christopher J; Thauvin-Robinet, Christel; Philippe, Christophe; Faivre, Laurence; Yalcin, Binnaz.
Afiliación
  • Denommé-Pichon AS; Functional Unit for Diagnostic Innovation in Rare Diseases, FHU-TRANSLAD, Dijon Bourgogne University Hospital, Dijon, France; UMR1231 GAD "Génétique des Anomalies du Développement", INSERM, FHU-TRANSLAD, University of Burgundy, Dijon, France; European Reference Network, ERN-ITHACA. Electronic addres
  • Collins SC; UMR1231 GAD "Génétique des Anomalies du Développement", INSERM, FHU-TRANSLAD, University of Burgundy, Dijon, France.
  • Bruel AL; Functional Unit for Diagnostic Innovation in Rare Diseases, FHU-TRANSLAD, Dijon Bourgogne University Hospital, Dijon, France; UMR1231 GAD "Génétique des Anomalies du Développement", INSERM, FHU-TRANSLAD, University of Burgundy, Dijon, France.
  • Mikhaleva A; Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland.
  • Wagner C; UMR7104, U964, INSERM, IGBMC, Illkirch, France.
  • Vancollie VE; Wellcome Sanger Institute, Hinxton, Cambridge, United Kingdom.
  • Thomas Q; UMR1231 GAD "Génétique des Anomalies du Développement", INSERM, FHU-TRANSLAD, University of Burgundy, Dijon, France; Department of Neurology, Dijon Bourgogne University Hospital, Dijon, France.
  • Chevarin M; Functional Unit for Diagnostic Innovation in Rare Diseases, FHU-TRANSLAD, Dijon Bourgogne University Hospital, Dijon, France; UMR1231 GAD "Génétique des Anomalies du Développement", INSERM, FHU-TRANSLAD, University of Burgundy, Dijon, France.
  • Weber M; UMR1231 GAD "Génétique des Anomalies du Développement", INSERM, FHU-TRANSLAD, University of Burgundy, Dijon, France; Department of Genetics and Reference Center for Development Disorders and Intellectual Disabilities, FHU-TRANSLAD and GIMI Institute, Dijon Bourgogne University Hospital, Dijon, Franc
  • Prada CE; Division of Genetics, Birth Defects & Metabolism, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.
  • Overs A; Functional Unit for Diagnostic Innovation in Rare Diseases, FHU-TRANSLAD, Dijon Bourgogne University Hospital, Dijon, France; UMR1231 GAD "Génétique des Anomalies du Développement", INSERM, FHU-TRANSLAD, University of Burgundy, Dijon, France.
  • Palomares-Bralo M; European Reference Network, ERN-ITHACA; Institute of Medical and Molecular Genetics (INGEMM), La Paz University Hospital, Autonomous University of Madrid, IdiPAZ, Madrid, Spain; Rare Diseases Networking Biomedical Research Centre (CIBERER), Carlos III Institute, Madrid, Spain.
  • Santos-Simarro F; European Reference Network, ERN-ITHACA; Institute of Medical and Molecular Genetics (INGEMM), La Paz University Hospital, Autonomous University of Madrid, IdiPAZ, Madrid, Spain; Rare Diseases Networking Biomedical Research Centre (CIBERER), Carlos III Institute, Madrid, Spain.
  • Pacio-Míguez M; Rare Diseases Networking Biomedical Research Centre (CIBERER), Carlos III Institute, Madrid, Spain.
  • Busa T; Department of Medical Genetics, CHU Timone Enfants, AP-HM, Marseille, France.
  • Legius E; Laboratory for Neurofibromatosis Research, Department of Human Genetics, KU Leuven University Hospital, Belgium.
  • Bacino CA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX.
  • Rosenfeld JA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX; Baylor Genetics Laboratories, Houston, TX.
  • Le Guyader G; Genetics Department, Poitiers University Hospital, Poitiers, France; University of Poitiers, Poitiers, France.
  • Egloff M; Genetics Department, Poitiers University Hospital, Poitiers, France; University of Poitiers, Poitiers, France; Experimental and Clinical Neurosciences Laboratory, INSERM, University of Poitiers, Poitiers, France.
  • Le Guillou X; Genetics Department, Poitiers University Hospital, Poitiers, France; University of Poitiers, Poitiers, France.
  • Mencarelli MA; Medical Genetics, Azienda Ospedaliero-Universitaria Senese, Siena, Italy.
  • Renieri A; Medical Genetics, Azienda Ospedaliero-Universitaria Senese, Siena, Italy; Medical Genetics, University of Siena, Siena, Italy; Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
  • Grosso S; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy; U.O.C. Pediatria, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
  • Levy J; Genetics Department, Robert-Debré University Hospital, APHP, Paris, France.
  • Dozières B; Department of Pediatric Neurology and Metabolic Diseases, Robert Debré University Hospital, APHP, Paris, France.
  • Desguerre I; Departments of Pediatric Neurology and Medical Genetics, Hôpital Necker-Enfants Malades, Université Paris Cité, Paris, France.
  • Vitobello A; Functional Unit for Diagnostic Innovation in Rare Diseases, FHU-TRANSLAD, Dijon Bourgogne University Hospital, Dijon, France; UMR1231 GAD "Génétique des Anomalies du Développement", INSERM, FHU-TRANSLAD, University of Burgundy, Dijon, France; European Reference Network, ERN-ITHACA.
  • Duffourd Y; Functional Unit for Diagnostic Innovation in Rare Diseases, FHU-TRANSLAD, Dijon Bourgogne University Hospital, Dijon, France; UMR1231 GAD "Génétique des Anomalies du Développement", INSERM, FHU-TRANSLAD, University of Burgundy, Dijon, France.
  • Lelliott CJ; Wellcome Sanger Institute, Hinxton, Cambridge, United Kingdom.
  • Thauvin-Robinet C; Functional Unit for Diagnostic Innovation in Rare Diseases, FHU-TRANSLAD, Dijon Bourgogne University Hospital, Dijon, France; UMR1231 GAD "Génétique des Anomalies du Développement", INSERM, FHU-TRANSLAD, University of Burgundy, Dijon, France; Department of Genetics and Reference Center for Developme
  • Philippe C; Functional Unit for Diagnostic Innovation in Rare Diseases, FHU-TRANSLAD, Dijon Bourgogne University Hospital, Dijon, France; UMR1231 GAD "Génétique des Anomalies du Développement", INSERM, FHU-TRANSLAD, University of Burgundy, Dijon, France.
  • Faivre L; UMR1231 GAD "Génétique des Anomalies du Développement", INSERM, FHU-TRANSLAD, University of Burgundy, Dijon, France; European Reference Network, ERN-ITHACA; Department of Genetics and Reference Center for Development Disorders and Intellectual Disabilities, FHU-TRANSLAD and GIMI Institute, Dijon Bou
  • Yalcin B; UMR1231 GAD "Génétique des Anomalies du Développement", INSERM, FHU-TRANSLAD, University of Burgundy, Dijon, France. Electronic address: binnaz.yalcin@inserm.fr.
Genet Med ; 25(7): 100835, 2023 Jul.
Article en En | MEDLINE | ID: mdl-36999555
ABSTRACT

PURPOSE:

Miller-Dieker syndrome is caused by a multiple gene deletion, including PAFAH1B1 and YWHAE. Although deletion of PAFAH1B1 causes lissencephaly unambiguously, deletion of YWHAE alone has not clearly been linked to a human disorder.

METHODS:

Cases with YWHAE variants were collected through international data sharing networks. To address the specific impact of YWHAE loss of function, we phenotyped a mouse knockout of Ywhae.

RESULTS:

We report a series of 10 individuals with heterozygous loss-of-function YWHAE variants (3 single-nucleotide variants and 7 deletions <1 Mb encompassing YWHAE but not PAFAH1B1), including 8 new cases and 2 follow-ups, added with 5 cases (copy number variants) from literature review. Although, until now, only 1 intragenic deletion has been described in YWHAE, we report 4 new variants specifically in YWHAE (3 splice variants and 1 intragenic deletion). The most frequent manifestations are developmental delay, delayed speech, seizures, and brain malformations, including corpus callosum hypoplasia, delayed myelination, and ventricular dilatation. Individuals with variants affecting YWHAE alone have milder features than those with larger deletions. Neuroanatomical studies in Ywhae-/- mice revealed brain structural defects, including thin cerebral cortex, corpus callosum dysgenesis, and hydrocephalus paralleling those seen in humans.

CONCLUSION:

This study further demonstrates that YWHAE loss-of-function variants cause a neurodevelopmental disease with brain abnormalities.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Lisencefalia / Lisencefalias Clásicas y Heterotopias Subcorticales en Banda / Trastornos del Neurodesarrollo / Discapacidad Intelectual Tipo de estudio: Etiology_studies Límite: Animals / Humans Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Lisencefalia / Lisencefalias Clásicas y Heterotopias Subcorticales en Banda / Trastornos del Neurodesarrollo / Discapacidad Intelectual Tipo de estudio: Etiology_studies Límite: Animals / Humans Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2023 Tipo del documento: Article